Effect on neonatal hyperbilirubinemia of phenobarbital during pregnancy or after birth: practical value of the treatment in a population with high risk of unexplained severe neonatal jaundice.
D000017:ABO Blood-Group System / Q000032:analysis; D000284:Administration, Oral; D000367:Age Factors; D001663:Bilirubin / Q000097:blood / Q000378:metabolism; D001724:Birth Weight; D002986:Clinical Trials as Topic; D005260:Female; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000097:blood; D006115:Greece; D006801:Humans; D007231:Infant, Newborn; D007567:Jaundice, Neonatal / Q000517:prevention & control*; D008297:Male; D008431:Maternal-Fetal Exchange; D010634:Phenobarbital / Q000008:administration & dosage / Q000627:therapeutic use*; D010919:Placebos; D011247:Pregnancy; D012494:Sampling Studies; D012737:Sex Factors; D013997:Time Factors
D000017:ABO Blood-Group System; D010919:Placebos; D001663:Bilirubin; D010634:Phenobarbital